Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PLEC | Q15149 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19460597 | 1.00 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12416684 | 0.89 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3795096 | 0.89 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12416947 | 0.89 | CA2 (0.61) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12417133 | 0.89 | CA2 (0.61) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL6936827 | 0.87 | SMN1; SMN2 (0.49) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL19460778 | 0.86 | KMT2A (0.57) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12416627 | 0.86 | KMT2A (0.57) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL11682122 | 0.86 | SMN1; SMN2 (0.50) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL11682120 | 0.86 | SMN1; SMN2 (0.50) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3469576-B1 | MULTI-LAYER DISPLAY WITH COLOR AND CONTRAST ENHANCEMENT | SAMSUNG ELECTRONICS CO LTD (KR) | 2024-07-03 | — | — | EP | disclosed |
| US-10565925-B2 | Full color display with intrinsic transparency | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-18 | — | — | US | disclosed |
| US-10554962-B2 | Multi-layer high transparency display for light field generation | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-04 | — | — | US | disclosed |
| US-10453371-B2 | Multi-layer display with color and contrast enhancement | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-10375365-B2 | Projection system with enhanced color and contrast | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-08-06 | — | — | US | disclosed |
| EP-3479163-A1 | MULTI-LAYER HIGH TRANSPARENCY DISPLAY FOR LIGHT FIELD GENERATION | Samsung Electronics Co., Ltd. (KR) | 2019-05-08 | — | — | EP | disclosed |
| EP-3469576-A1 | MULTI-LAYER DISPLAY WITH COLOR AND CONTRAST ENHANCEMENT | Samsung Electronics Co., Ltd. (KR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3469791-A1 | PROJECTION SYSTEM WITH ENHANCED COLOR AND CONTRAST | Samsung Electronics Co., Ltd. (KR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3455845-A1 | FULL COLOR DISPLAY WITH INTRINSIC TRANSPARENCY | Samsung Electronics Co., Ltd. (KR) | 2019-03-20 | — | — | EP | disclosed |
| US-20170310940-A1 | PROJECTION SYSTEM WITH ENHANCED COLOR AND CONTRAST | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-10-26 | — | — | US | disclosed |
| US-20170309215-A1 | MULTI-LAYER DISPLAY WITH COLOR AND CONTRAST ENHANCEMENT | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-10-26 | — | — | US | disclosed |
| US-20170310956-A1 | MULTI-LAYER HIGH TRANSPARENCY DISPLAY FOR LIGHT FIELD GENERATION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-10-26 | — | — | US | disclosed |
| US-20170301288-A1 | FULL COLOR DISPLAY WITH INTRINSIC TRANSPARENCY | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-10-19 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | L3MBTL1 2487/4885ALDH1A1 3768/4885SMN1; SMN2 1896/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | L3MBTL1 2487/4885ALDH1A1 3768/4885SMN1; SMN2 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.